A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).

Joline Si Jing Lim,Andrea Li Ann Wong,Samuel Guan Wei Ow,Lim Siew Eng,Raghav Sundar,Gloria Hj Chan,Kritika Yadav,Valerie Heong,David S.P. Tan,Ross A. Soo,Cheng Ean Chee,Wei Peng Yong,Boon C. Goh,Soo-Chin Lee

A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).

2019

Joline Si Jing Lim
Andrea Li Ann Wong
Samuel Guan Wei Ow
Lim Siew Eng
Raghav Sundar
Gloria Hj Chan
Kritika Yadav
Valerie Heong
David S.P. Tan
Ross A. Soo
Cheng Ean Chee
Wei Peng Yong
Boon C. Goh
Soo-Chin Lee

1045Background: Endocrine blockade (EB) is standard of care for patients (pts) with HR+ LABC/MBC. RET over-expression (RET+) occurs in up to 75% of HR+ breast cancers and is a postulated mechanism ...

Keywords:

Lenvatinib
Blockade
Pharmacodynamics
Endocrine system
Hormone receptor
Letrozole
Pathology
Oncology
Internal medicine
Metastatic breast cancer
Medicine
postmenopausal women

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations